460 related articles for article (PubMed ID: 33619920)
1. Preparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and Implications.
Jung J
J Korean Med Sci; 2021 Feb; 36(7):e59. PubMed ID: 33619920
[TBL] [Abstract][Full Text] [Related]
2. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
3. Herd immunity: challenges and the way forward in Korea.
Oh J; Kim S; Ryu B; Shin M; Kim BI
Epidemiol Health; 2021; 43():e2021054. PubMed ID: 34412446
[TBL] [Abstract][Full Text] [Related]
4. Contact-adjusted Immunity Levels against SARS-CoV-2 in Korea and Prospects for Achieving Herd Immunity.
Chun JY; Jeong H; Kim Y
J Korean Med Sci; 2021 Oct; 36(38):e272. PubMed ID: 34609093
[TBL] [Abstract][Full Text] [Related]
5. Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters.
Burckhardt RM; Dennehy JJ; Poon LLM; Saif LJ; Enquist LW
J Virol; 2022 Feb; 96(3):e0197321. PubMed ID: 34817198
[TBL] [Abstract][Full Text] [Related]
6. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.
Yoo JH
J Korean Med Sci; 2021 Feb; 36(6):e54. PubMed ID: 33559409
[TBL] [Abstract][Full Text] [Related]
7. Toward Achieving a Vaccine-Derived Herd Immunity Threshold for COVID-19 in the U.S.
Gumel AB; Iboi EA; Ngonghala CN; Ngwa GA
Front Public Health; 2021; 9():709369. PubMed ID: 34368071
[TBL] [Abstract][Full Text] [Related]
8. Herd immunization with childhood vaccination may provide protection against COVID-19.
Yu Y
Acta Microbiol Immunol Hung; 2020 Sep; 67(3):198-200. PubMed ID: 32986604
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccinations: The unknowns, challenges, and hopes.
Mohamed K; Rzymski P; Islam MS; Makuku R; Mushtaq A; Khan A; Ivanovska M; Makka SA; Hashem F; Marquez L; Cseprekal O; Filgueiras IS; Fonseca DLM; Mickael E; Ling I; Arero AG; Cuschieri S; Minakova K; Rodríguez-Román E; Abarikwu SO; Faten AB; Grancini G; Cabral-Marques O; Rezaei N
J Med Virol; 2022 Apr; 94(4):1336-1349. PubMed ID: 34845731
[TBL] [Abstract][Full Text] [Related]
11. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
12. Promise and challenges in the development of COVID-19 vaccines.
Chen W
Hum Vaccin Immunother; 2020 Nov; 16(11):2604-2608. PubMed ID: 32703069
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity.
Kouamou V; Matarise R; Santos ED; Elose N; Manasa J
Pan Afr Med J; 2021; 39():255. PubMed ID: 34707756
[TBL] [Abstract][Full Text] [Related]
14. Challenges of vaccination and herd immunity in COVID-19 and management strategies.
She J; Hou D; Chen C; Bi J; Song Y
Clin Respir J; 2022 Nov; 16(11):708-716. PubMed ID: 36172975
[TBL] [Abstract][Full Text] [Related]
15. Return to normal pre-COVID-19 life is delayed by inequitable vaccine allocation and SARS-CoV-2 variants.
Liu F; Zhao Z; Ma C; Nie X; Wu A; Li X
Epidemiol Infect; 2022 Jan; 150():e46. PubMed ID: 35067231
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
Liu Q; Qin C; Liu M; Liu J
Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes.
AlJamaan F; Temsah MH; Alhasan K; Alenezi S; Alhaboob A; Alrabiaah A; Batais M; Alshahrani F; Assiri RA; Bafaqih H; Alaraj A; Al Qadrah B; Alhaidary A; Saad K; Saddik B; Halwani R; Rabaan AA; Al-Subaie S; Barry M; Al-Tawfiq JA
J Infect Public Health; 2022 Jul; 15(7):773-780. PubMed ID: 35728424
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Variants, Vaccines, and Host Immunity.
Mistry P; Barmania F; Mellet J; Peta K; Strydom A; Viljoen IM; James W; Gordon S; Pepper MS
Front Immunol; 2021; 12():809244. PubMed ID: 35046961
[TBL] [Abstract][Full Text] [Related]
19. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
[TBL] [Abstract][Full Text] [Related]
20. Looking beyond COVID-19 vaccine phase 3 trials.
Kim JH; Marks F; Clemens JD
Nat Med; 2021 Feb; 27(2):205-211. PubMed ID: 33469205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
